Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Antimicrobial activities of fidaxomicin.
Goldstein EJ, Babakhani F, Citron DM. Goldstein EJ, et al. Among authors: babakhani f. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339. Clin Infect Dis. 2012. PMID: 22752863 Free PMC article.
Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
Babakhani F, Seddon J, Sears P. Babakhani F, et al. Antimicrob Agents Chemother. 2014 May;58(5):2934-7. doi: 10.1128/AAC.02572-13. Epub 2014 Feb 18. Antimicrob Agents Chemother. 2014. PMID: 24550338 Free PMC article.
Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
Eyre DW, Babakhani F, Griffiths D, Seddon J, Del Ojo Elias C, Gorbach SL, Peto TE, Crook DW, Walker AS. Eyre DW, et al. Among authors: babakhani f. J Infect Dis. 2014 May 1;209(9):1446-51. doi: 10.1093/infdis/jit598. Epub 2013 Nov 11. J Infect Dis. 2014. PMID: 24218500 Free PMC article. Clinical Trial.
Fidaxomicin inhibits toxin production in Clostridium difficile.
Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Babakhani F, et al. J Antimicrob Chemother. 2013 Mar;68(3):515-22. doi: 10.1093/jac/dks450. Epub 2012 Dec 2. J Antimicrob Chemother. 2013. PMID: 23208832
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
Allen CA, Babakhani F, Sears P, Nguyen L, Sorg JA. Allen CA, et al. Among authors: babakhani f. Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12. Antimicrob Agents Chemother. 2013. PMID: 23147724 Free PMC article.
Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Babakhani F, et al. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453. Clin Infect Dis. 2012. PMID: 22752866 Free PMC article.
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Nerandzic MM, et al. Among authors: babakhani f. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S121-6. doi: 10.1093/cid/cis440. Clin Infect Dis. 2012. PMID: 22752860 Free PMC article. Clinical Trial.
Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Petrella LA, et al. Among authors: babakhani f. Clin Infect Dis. 2012 Aug;55(3):351-7. doi: 10.1093/cid/cis430. Epub 2012 Apr 20. Clin Infect Dis. 2012. PMID: 22523271 Free PMC article. Clinical Trial.
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Goldstein EJ, et al. Among authors: babakhani f. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844318 Free PMC article. Clinical Trial.
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
Babakhani F, Gomez A, Robert N, Sears P. Babakhani F, et al. J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24. J Med Microbiol. 2011. PMID: 21349983 Free PMC article.
Exposure to OP-1118 (at 4× MIC) also resulted in a ≥3 log drop in c.f.u. counts for the ATCC 43255 strain, the clinical BI strain ORG 1687 and the mutant strain ORG 919. Higher concentrations of OP-1118 (32× MIC) were required for a 3 log reduction in c.f.u. counts …
Exposure to OP-1118 (at 4× MIC) also resulted in a ≥3 log drop in c.f.u. counts for the ATCC 43255 strain, the clinical BI strain ORG …
23 results
Jump to page
Feedback